The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma
- 11 January 2024
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 143 (2) , 152-165
Abstract
Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma associated with immunodeficiency, characterized by uncertain treatment approaches and an unfavorable prognosis. We conducted a multicenter, international, retrospective cohort study, aiming to characterize the clinical features, risk factors, and outcomes of patients with PBL. Data were collected from 22 institutions across 4 countries regarding patients diagnosed with PBL between 1 January 1999 and 31 December 2020. Survival risk factors were analyzed using both univariate and multivariate regression models. Overall survival (OS) was calculated using Kaplan-Meier statistics. First-line treatment regimens were stratified into standard- and higher-intensity regimens, and based on whether they incorporated a proteasome inhibitor (PI). A total of 281 patients (median age, 55 years) were included. Immunodeficiency of any kind was identified in 144 patients (51%), and 99 patients (35%) had HIV-positive results. The 5-year OS for the entire cohort was 36% (95% confidence interval, 30%-42%). In multivariate analysis, inferior OS was associated with Epstein-Barr virus–negative lymphoma, poor performance status, advanced stage, and bone marrow involvement. In an independent univariate analysis, the international prognostic index was associated with OS outcomes. Neither immunosuppression nor HIV infection, specifically, influenced OS. Among patients treated with curative intent (n = 234), the overall response rate was 72%. Neither the intensity of the treatment regimen nor the inclusion of PIs in first-line therapy was associated with OS. In this large retrospective study of patients with PBL, we identified novel risk factors for survival. PBL remains a challenging disease with poor long-term outcomes.Keywords
This publication has 30 references indexed in Scilit:
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Clinicopathologic Comparison of Plasmablastic Lymphoma in HIV-positive, Immunocompetent, and Posttransplant PatientsAmerican Journal of Surgical Pathology, 2014
- Plasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center's experienceLeukemia & Lymphoma, 2014
- Brentuximab Vedotin Demonstrates Activity in a Patient With Plasmablastic Lymphoma Arising From a Background of Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2013
- Human immunodeficiency virus‐associated plasmablastic lymphomaCancer, 2012
- Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1Haematologica, 2011
- HIV-Negative Plasmablastic Lymphoma: Not in the MouthClinical Lymphoma Myeloma and Leukemia, 2011
- Patient With HIV-Associated Plasmablastic Lymphoma Responding to Bortezomib Alone and in Combination With Dexamethasone, Gemcitabine, Oxaliplatin, Cytarabine, and Pegfilgrastim Chemotherapy and Lenalidomide AloneJournal of Clinical Oncology, 2010
- Prognostic Factors in Chemotherapy-Treated Patients with HIV-Associated Plasmablastic LymphomaThe Oncologist, 2010
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993